

Supplementary Table 4. Baseline information of patients in the third analysis, SCL effects on surgical interventions.

	SCL-on (n = 16)	SCL-off (n = 22)	
Sex (male:female)	11:5	13:9	$P = 0.735^a$
Average age at the starting point	44.9±13.5	41.4±15.6	$P = 0.475^b$
Visual acuity at the starting point (logMAR)	1.00±0.74	1.13±1.05	$P = 0.682^b$
Rate of p.Gln118Ter mutation and other mutations	10:6 (Among the 6 eyes, 2 eyes had p.Gln211ArgfsTer, 60, 2 eyes had p.Ile156Asn, and 2 were unknown)	11:11 (Among the 11 eyes, 2 eyes had p.Gln211ArgfsTer, 60, and 9 were unknown)	$P = 0.521^a$

a: Fisher's exact test, b: *t*-test,

Patients and the clinical features in the third analysis, which included all 40 eyes of the 20 patients, except for 2 eyes excluded due to absence of sufficient clinical examinations. The patient population included 16 eyes in SCL-on and 22 eyes in SCL-off groups. Deleterious mutations in *TACSTD2* in both alleles were detected in 27 eyes; for the remaining eyes, mutation analyses were not performed.